rs137962929
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_198428.3(BBS9):c.263+1G>A variant causes a splice donor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000118 in 1,613,742 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_198428.3 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS9 | NM_198428.3 | c.263+1G>A | splice_donor_variant | ENST00000242067.11 | NP_940820.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS9 | ENST00000242067.11 | c.263+1G>A | splice_donor_variant | 1 | NM_198428.3 | ENSP00000242067 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152044Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251282Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135810
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1461580Hom.: 0 Cov.: 33 AF XY: 0.00000963 AC XY: 7AN XY: 727078
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152162Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74398
ClinVar
Submissions by phenotype
Bardet-Biedl syndrome 9 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Dec 20, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Aug 10, 2023 | - - |
BBS9-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 16, 2023 | The BBS9 c.263+1G>A variant is predicted to disrupt the GT donor site and interfere with normal splicing. This canonical splice variant has been reported in the homozygous state in an individual with Bardet-Biedl syndrome (Fattahi et al. 2014. PubMed ID: 24849935). This variant is reported in 0.012% of alleles in individuals of African descent in gnomAD. Variants that disrupt the consensus splice donor site in BBS9 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Bardet-Biedl syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 08, 2023 | For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site results in insertion of 4 nucleotides between exons 3 and 4 and introduces a new termination codon (PMID: 24849935). However the mRNA is not expected to undergo nonsense-mediated decay. ClinVar contains an entry for this variant (Variation ID: 412264). Disruption of this splice site has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 24849935). This variant is present in population databases (rs137962929, gnomAD 0.01%). This sequence change affects a donor splice site in intron 3 of the BBS9 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely disrupts the C-terminus of the protein. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at